» Articles » PMID: 36400660

Relative Effectiveness of a 2nd Booster Dose of COVID-19 MRNA Vaccine Up to Four Months Post Administration in Individuals Aged 80 years or More in Italy: A Retrospective Matched Cohort Study

Abstract

Several countries started a 2nd booster COVID-19 vaccination campaign targeting the elderly population, but evidence around its effectiveness is still scarce. This study aims to estimate the relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine in the population aged ≥ 80 years in Italy, during predominant circulation of the Omicron BA.2 and BA.5 subvariants. We linked routine data from the national vaccination registry and the COVID-19 surveillance system. On each day between 11 April and 6 August 2022, we matched 1:1, according to several demographic and clinical characteristics, individuals who received the 2nd booster vaccine dose with individuals who received the 1st booster vaccine dose at least 120 days earlier. We used the Kaplan-Meier method to compare the risks of SARS-CoV-2 infection and severe COVID-19 (hospitalisation or death) between the two groups, calculating the relative vaccine effectiveness (RVE) as (1 - risk ratio)X100. Based on the analysis of 831,555 matched pairs, we found that a 2nd booster dose of mRNA vaccine, 14-118 days post administration, was moderately effective in preventing SARS-CoV-2 infection compared to a 1st booster dose administered at least 120 days earlier [14.3 %, 95 % confidence interval (CI): 2.2-20.2]. RVE decreased from 28.5 % (95 % CI: 24.7-32.1) in the time-interval 14-28 days to 7.6 % (95 % CI: -14.1 to 18.3) in the time-interval 56-118 days. However, RVE against severe COVID-19 was higher (34.0 %, 95 % CI: 23.4-42.7), decreasing from 43.2 % (95 % CI: 30.6-54.9) to 27.2 % (95 % CI: 8.3-42.9) over the same time span. Although RVE against SARS-CoV-2 infection was much reduced 2-4 months after a 2nd booster dose, RVE against severe COVID-19 was about 30 %, even during prevalent circulation of the Omicron BA.5 subvariant. The cost-benefit of a 3rd booster dose for the elderly people who received the 2nd booster dose at least four months earlier should be carefully evaluated.

Citing Articles

The Impact of Vaccination on COVID-19 Outcomes in Vietnam.

Nguyen N, Nguyen H, Le-Quy V, To T, Tran H, Nguyen T Diagnostics (Basel). 2025; 14(24.

PMID: 39767211 PMC: 11674964. DOI: 10.3390/diagnostics14242850.


A Response to: A Letter to the Editor Regarding 'Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework'.

Beck E, Bausch-Jurken M, Van de Velde N, Wang X, Malmenas M Infect Dis Ther. 2024; 13(10):2195-2202.

PMID: 39180646 PMC: 11416437. DOI: 10.1007/s40121-024-01020-2.


Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study.

Lazar Neto F, Hitchings M, Amin A, de Franca G, Lind M, Scaramuzzini Torres M Lancet Reg Health Am. 2024; 34:100755.

PMID: 38737773 PMC: 11087726. DOI: 10.1016/j.lana.2024.100755.


Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.

Meah S, Shi X, Fritsche L, Salvatore M, Wagner A, Martin E Sci Adv. 2023; 9(51):eadj3747.

PMID: 38117882 PMC: 10732535. DOI: 10.1126/sciadv.adj3747.


Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case-Control Study Based on the French National Health Data System.

Semenzato L, Botton J, Le Vu S, Jabagi M, Cuenot F, Drouin J Open Forum Infect Dis. 2023; 10(10):ofad460.

PMID: 37808897 PMC: 10551849. DOI: 10.1093/ofid/ofad460.


References
1.
Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L . Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022; 386(18):1712-1720. PMC: 9006780. DOI: 10.1056/NEJMoa2201570. View

2.
Hernan M, Robins J . Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016; 183(8):758-64. PMC: 4832051. DOI: 10.1093/aje/kwv254. View

3.
Graham M, May A, Varsavsky T, Sudre C, Murray B, Klaser K . Knowledge barriers in a national symptomatic-COVID-19 testing programme. PLOS Glob Public Health. 2023; 2(1):e0000028. PMC: 10022193. DOI: 10.1371/journal.pgph.0000028. View

4.
Link-Gelles R, Levy M, Gaglani M, Irving S, Stockwell M, Dascomb K . Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(29):931-939. PMC: 9310634. DOI: 10.15585/mmwr.mm7129e1. View

5.
Cohen M, Oster Y, Moses A, Spitzer A, Benenson S . Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA Netw Open. 2022; 5(8):e2224657. PMC: 9346545. DOI: 10.1001/jamanetworkopen.2022.24657. View